Bladder cancer battle: which chemo regimen wins before or after surgery?
NCT ID NCT01812369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different chemotherapy drug combinations in 500 people with advanced bladder cancer that had not spread to other organs. The goal was to see which treatment worked better at stopping the cancer from coming back after surgery. Participants received either gemcitabine plus cisplatin or a stronger version of MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) before or after bladder removal surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UHRouen
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Can One-Piece tumour removal improve bladder cancer outcomes?